Building new business pillars beyond the photomask business
First written in FY2016. 10 of 22 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1Solution business: lower revenue and a wider operating lossAnnual report
「In the Solutions Business, sales of Extreme Tag declined in the RFID field. Interim consolidated accounting period of the fiscal year ending September 2025 Interim consolidated accounting period of the fiscal year ending September 2026 Change Revenue ¥38 million ¥35 million -8.8% Operating profit (¥134 million) (¥154 million) —」
Solutions Business revenue declined 8.8%, from ¥38 million to ¥35 million, due to lower sales of Extreme Tag, while the operating loss widened from ¥134.51 million to ¥154.581 million. - FY2025Solution business: lower revenue and a wider operating lossAnnual report
「In the Solutions Business, sales of Extreme Tag increased in the RFID field for use in managing consumables for equipment, while sales of the Digital Colposcope Q-CO declined in the healthcare field.」
The Solutions Business, positioned as a new business pillar, recorded revenue of ¥84 million, down 2.9% year on year, and an operating loss of ¥280 million. The loss widened from the previous year's operating loss of ¥271 million. - FY2025-H1Solutions Business revenue declined, but the operating loss narrowedAnnual report
「In the Solutions Business, sales of the Digital Colposcope Q-CO declined in the healthcare field. Revenue ¥47 million ¥38 million -17.9% Operating profit (¥146 million) (¥134 million) —」
The Solutions Business, positioned as a new business pillar, recorded lower revenue due to declining sales of healthcare products, while the operating loss narrowed from ¥146.189 million in the same period of the previous year to ¥134.51 million. - FY2024AdvancedAnnual report
「As a new business following the photomask business, we are currently pursuing opportunities in the RFID and healthcare fields and aiming to achieve profitability at an early stage. In the RFID field, we are working to expand sales of Extreme Tag, while in the healthcare field we are working to expand sales of the Digital Colposcope Q-CO and WILMO electrical stimulation device. We will also work to expand our product lineup and develop new proprietary products. In addition, we will continue to consider entering new fields and pursuing M&A.」
For the new business, the objective was made more specific, shifting from early commercialization to achieving profitability at an early stage. The company continues to expand sales of RFID and healthcare products, broaden its product lineup, develop proprietary products, and consider entry into new fields and M&A. The Solutions Business recorded revenue of ¥86 million and an operating loss of ¥271 million, representing higher revenue and a narrower operating loss year on year. - FY2024-Q2Solutions Business revenue increased and the operating loss narrowedAnnual report
「Revenue ¥43 million ¥47 million +7.4% Operating profit (¥156 million) (¥146 million) —」
Solutions Business revenue increased 7.4% year on year, while the operating loss narrowed from ¥156.589 million to ¥146.189 million. - FY2024-Q1Solutions Business revenue declined, but the operating loss narrowedAnnual report
「Revenue ¥15 million ¥11 million -26.4% Operating profit (¥100 million) (¥96 million) —」
Solutions Business revenue declined 26.4% year on year, from ¥15 million to ¥11 million, while the operating loss narrowed from ¥100 million to ¥96 million. - FY2023-Q3Solutions Business revenue increased, but the operating loss widenedAnnual report
「In the Solutions Business, sales in the RFID field declined, but sales in the healthcare field increased, resulting in higher segment revenue. Operating profit, however, deteriorated as costs incurred to establish a new revenue base increased. Revenue ¥50 million ¥58 million +16.8% Operating profit (¥185 million) (¥222 million) —」
The Solutions Business returned to revenue growth after revenue had declined through the previous quarter, while the operating loss widened from ¥185 million to ¥222 million due to higher costs incurred to establish a new revenue base. - FY2023-Q2Decline in profit due to costs incurred to establish the Solutions Business's revenue baseAnnual report
「In the Solutions Business, sales in the healthcare field increased, but sales in the RFID field declined. As a result, segment revenue decreased, while operating profit declined due mainly to higher costs incurred to establish a new revenue base.」
The Solutions Business, which is being developed as a new business pillar, saw healthcare sales increase but RFID sales decline. As higher costs to establish a new revenue base caused the operating loss to widen from ¥110 million in the same period of the previous year to ¥157 million, - FY2023-Q1AdvancedAnnual report
「The company has presented information by segment since the first quarter of the current fiscal year. Previously, the group consisted solely of the single Large Photomask Business segment, but it has made the Solutions Business an independent reportable segment, bringing the total to 2.」
The solution business, including businesses outside the photomask business, was formally classified as an independent reporting segment. This indicates that the organization and disclosure relating to the new business pillars have become more concrete. - FY2022AdvancedAnnual report
「As new businesses following the photomask business, the company is currently pursuing opportunities in the RFID and healthcare fields with the aim of early commercialization. In the RFID field, it is working to expand sales of Extreme Tag, which was launched during the current fiscal year. In the healthcare field, it is working to expand sales of the Digital Colposcope Q-CO and the electrical stimulation device WILMO, while seeking regulatory approval for WILMO in China, following Japan and Taiwan.」
The company narrowed the scope of its new businesses to RFID and healthcare and identified specific measures, including the launch of Extreme Tag, expanded sales of existing healthcare products and regulatory approval for WILMO in China. - FY2022-Q3RestatedAnnual report
「There were no material changes during the nine-month period of the current consolidated fiscal year in the group's management policies, management strategies or other matters.」
It is stated that there have been no material changes in management policies, management strategies or other matters, including the building of new business pillars. - FY2022-Q1RestatedAnnual report
「There were no material changes during the first quarter of the current consolidated cumulative period in the Group's management policies, management strategies or other related matters.」
It is stated that there have been no material changes in management policies, management strategies or other matters, including the building of new business pillars outside the photomask business. - FY2021RestatedAnnual report
「As new businesses following the photomask business, the company is currently pursuing opportunities in the RFID and healthcare fields. It will actively work to expand its product range, develop new proprietary products and secure sales channels, including overseas channels, with the aim of early commercialization. It will also conduct market research in multiple fields and continue considering market entry.」
The policy of early commercialization through product-range expansion, proprietary product development, securing overseas sales channels and market research remains unchanged, with RFID and healthcare designated as the new business fields. - FY2021-Q3RestatedAnnual report
「There were no material changes during the nine-month period of the current consolidated fiscal year in the group's management policies, management strategies or other matters.」
It is stated that there have been no material changes in management policies, management strategies or other matters, including the building of new business pillars outside the photomask business. - FY2021-Q2RestatedAnnual report
「There were no material changes during the cumulative second quarter to the Group's management policies, management strategies or other related matters.」
It is stated that there have been no material changes in management policies, management strategies or other matters, including the building of new business pillars. - FY2020AdvancedAnnual report
「The company will actively pursue overseas expansion, an expanded product range and the development of new proprietary products, with the aim of commercializing them at an early stage.」
For the new business pillar following the photomask business, the target fields were specified as RFID and healthcare, and measures for early commercialization through overseas expansion, product-range expansion and the development of proprietary products became more concrete. - FY2020-Q3RestatedAnnual report
「There were no material changes during the nine-month period of the current consolidated fiscal year in the group's management policies, management strategies or other matters.」
It is stated that there have been no material changes in management policies, management strategies or other matters, including the building of new business pillars outside the photomask business. - FY2020-Q2RestatedAnnual report
「There were no material changes during the cumulative second quarter to the Group's management policies, management strategies or other related matters.」
It is stated that there have been no material changes in management policies, management strategies or other matters, including the building of new business pillars outside the photomask business. - FY2020-Q1RestatedAnnual report
「There were no material changes during the first quarter of the current consolidated cumulative period in the Group's management policies, management strategies or other related matters.」
It is stated that there have been no material changes in management policies, management strategies or other matters, including the building of new business pillars. - FY2019RestatedAnnual report
「The Group considers building new businesses outside the photomask business to be an urgent task and is currently working toward commercializing businesses in the printed electronics, RFID and healthcare fields.」
The policy of building new business pillars outside the photomask business remains unchanged, with printed electronics, RFID and healthcare continuing to be targeted for commercialization. - FY2018RestatedAnnual report
「Believing that building new business pillars outside the photomask business is an urgent task, the company will pursue the development of new businesses across all possibilities, in addition to the printed electronics, RFID and healthcare fields in which it is currently working toward commercialization.」
The policy of treating the building of new business pillars as an urgent task remains unchanged, with the scope expanded to include printed electronics, RFID, healthcare and other fields. - FY2016First statedAnnual report
「Building new business pillars outside the photomask business is the company's most urgent task.」
The company has identified building new business pillars outside its existing photomask business as its most urgent task.